Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions
- PMID: 16849680
- DOI: 10.1093/jnci/djj264
Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions
Abstract
Background: Randomized trials have yielded mixed results on the effects of treatment for Helicobacter pylori and little information on the effects of vitamins or garlic supplements on precancerous gastric lesions. We conducted a randomized trial to test the effects of one-time H. pylori treatment and long-term vitamin or garlic supplements in reducing the prevalence of advanced precancerous gastric lesions.
Methods: Most of the adults aged 35-64 years in 13 randomly selected villages in Linqu County, Shandong Province, China, were identified and given baseline endoscopies in 1994. In 1995, 3365 eligible subjects were randomly assigned in a factorial design to three interventions or placebos: amoxicillin and omeprazole for 2 weeks in 1995 (H. pylori treatment); vitamin C, vitamin E, and selenium for 7.3 years (vitamin supplement); and aged garlic extract and steam-distilled garlic oil for 7.3 years (garlic supplement). Subjects underwent endoscopies with biopsies in 1999 and 2003, and the prevalence of precancerous gastric lesions was determined by histopathologic examination of seven standard biopsy sites. The 3365 eligible randomized subjects represented 93.5% of those with baseline endoscopy and included all baseline histologic categories except gastric cancer. Only 0.18% had normal gastric mucosa. Logistic regression was used to estimate the intervention effects on the odds of advanced precancerous gastric lesions, and t-tests were used to assess effects on histologic severity. All statistical tests were two-sided.
Results: H. pylori treatment resulted in statistically significant decreases in the combined prevalence of severe chronic atrophic gastritis, intestinal metaplasia, dysplasia, or gastric cancer in 1999 (odds ratio [OR] = 0.77; 95% confidence interval [CI] = 0.62 to 0.95) and in 2003 (OR = 0.60; 95% CI = 0.47 to 0.75), and had favorable effects on the average histopathologic severity and on progression and regression of precancerous gastric lesions in 2003. H. pylori treatment did not reduce the combined prevalence of dysplasia or gastric cancer. However, fewer subjects receiving H. pylori treatment (19/1130; 1.7%) than receiving placebo (27/1128; 2.4%) developed gastric cancer (adjusted P = .14). No statistically significant favorable effects were seen for garlic or vitamin supplements.
Conclusion: H. pylori treatment reduces the prevalence of precancerous gastric lesions and may reduce gastric cancer incidence, but further data are needed to prove the latter point. Long-term vitamin or garlic supplementation had no beneficial effects on the prevalence of precancerous gastric lesions or on gastric cancer incidence.
Comment in
-
(Nutritional) chemoprevention of cancer: what's up?J Natl Cancer Inst. 2006 Jul 19;98(14):945-6. doi: 10.1093/jnci/djj293. J Natl Cancer Inst. 2006. PMID: 16849669 No abstract available.
-
Re: Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions.J Natl Cancer Inst. 2006 Oct 4;98(19):1426. doi: 10.1093/jnci/djj388. J Natl Cancer Inst. 2006. PMID: 17018791 No abstract available.
Similar articles
-
Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial.BMJ. 2019 Sep 11;366:l5016. doi: 10.1136/bmj.l5016. BMJ. 2019. PMID: 31511230 Free PMC article. Clinical Trial.
-
Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality.J Natl Cancer Inst. 2012 Mar 21;104(6):488-92. doi: 10.1093/jnci/djs003. Epub 2012 Jan 23. J Natl Cancer Inst. 2012. PMID: 22271764 Free PMC article. Clinical Trial.
-
Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data.Control Clin Trials. 1998 Aug;19(4):352-69. doi: 10.1016/s0197-2456(98)00016-6. Control Clin Trials. 1998. PMID: 9683311 Clinical Trial.
-
Helicobacter pylori associated gastric intestinal metaplasia: Treatment and surveillance.World J Gastroenterol. 2016 Jan 21;22(3):1311-20. doi: 10.3748/wjg.v22.i3.1311. World J Gastroenterol. 2016. PMID: 26811668 Free PMC article. Review.
-
Future candidates for indications of Helicobacter pylori eradication: do the indications need to be revised?J Gastroenterol Hepatol. 2012 Feb;27(2):200-11. doi: 10.1111/j.1440-1746.2011.06961.x. J Gastroenterol Hepatol. 2012. PMID: 22098099 Review.
Cited by
-
Diagnosis and management of high risk group for gastric cancer.Gut Liver. 2015 Jan;9(1):5-17. doi: 10.5009/gnl14118. Gut Liver. 2015. PMID: 25547086 Free PMC article. Review.
-
Chemoprevention Against Gastric Cancer.Gastrointest Endosc Clin N Am. 2021 Jul;31(3):519-542. doi: 10.1016/j.giec.2021.03.006. Gastrointest Endosc Clin N Am. 2021. PMID: 34053637 Free PMC article. Review.
-
The Effects of Antibiotics on the Development and Treatment of Non-Small Cell Lung Cancer.Pol J Microbiol. 2023 Dec 16;72(4):365-375. doi: 10.33073/pjm-2023-047. eCollection 2023 Dec 1. Pol J Microbiol. 2023. PMID: 38103006 Free PMC article.
-
Vitamin C supplementation does not protect L-gulono-gamma-lactone oxidase-deficient mice from Helicobacter pylori-induced gastritis and gastric premalignancy.Int J Cancer. 2008 Mar 1;122(5):1068-76. doi: 10.1002/ijc.23228. Int J Cancer. 2008. PMID: 17990318 Free PMC article.
-
Role of bacteria in oncogenesis.Clin Microbiol Rev. 2010 Oct;23(4):837-57. doi: 10.1128/CMR.00012-10. Clin Microbiol Rev. 2010. PMID: 20930075 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
